Cipla Ltd
CIPLACipla Ltd
CIPLAPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
29.17 | 5.07 | 0.87% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
43.14 | 6.21 | 0.54% |
Forecast & Ratings
Detailed Forecastfrom 31 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Cipla Limited is a pharmaceutical company. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology & cosmetology, diabetes, HIV/AIDS, infectious diseases & critical care, malaria etc.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 13,998.31 | 14,622.98 | 15,513.36 | 16,838.98 | 17,476.19 | 19,425.58 | 22,044.25 | 23,228.57 | 26,520.66 | 26,520.66 | ||||||||||
Raw Materials | 5,026.31 | 5,206.16 | 5,671.36 | 5,737.45 | 6,236.18 | 7,544.60 | 9,220.29 | 8,348.28 | 19,677.86 | 19,677.86 | ||||||||||
Power & Fuel Cost | 245.92 | 251.73 | 298.82 | 335.11 | 327.43 | 308.26 | 331.03 | 353.61 | ||||||||||||
Employee Cost | 2,434.01 | 2,633.82 | 2,690.10 | 2,856.53 | 3,027.01 | 3,251.83 | 3,529.91 | 3,830.08 | ||||||||||||
Selling & Administrative Expenses | 1,904.00 | 2,157.79 | 2,353.98 | 2,734.65 | 2,895.69 | 2,417.36 | 3,141.75 | 3,502.92 | ||||||||||||
Operating & Other expenses | 1,700.19 | 1,669.00 | 1,392.59 | 1,601.36 | 1,439.69 | 1,385.11 | 1,169.70 | 1,873.68 | ||||||||||||
EBITDA | 2,687.88 | 2,704.48 | 3,106.51 | 3,573.88 | 3,550.19 | 4,518.42 | 4,651.57 | 5,320.00 | 6,842.80 | 6,842.80 | ||||||||||
Depreciation/Amortization | 754.22 | 1,322.93 | 1,322.82 | 1,326.31 | 1,174.65 | 1,067.66 | 1,051.95 | 1,172.11 | 1,051.02 | 1,051.02 | ||||||||||
PBIT | 1,933.66 | 1,381.55 | 1,783.69 | 2,247.57 | 2,375.54 | 3,450.76 | 3,599.62 | 4,147.89 | 5,791.78 | 5,791.78 | ||||||||||
Interest & Other Items | 206.63 | 159.38 | 114.23 | 168.43 | 197.36 | 160.70 | 106.35 | 109.54 | 89.88 | 89.88 | ||||||||||
PBT | 1,727.03 | 1,222.17 | 1,669.46 | 2,079.14 | 2,178.18 | 3,290.06 | 3,493.27 | 4,038.35 | 5,701.90 | 5,701.90 | ||||||||||
Taxes & Other Items | 367.04 | 215.78 | 258.93 | 551.44 | 631.66 | 885.19 | 976.52 | 1,236.44 | 1,580.35 | 1,580.35 | ||||||||||
Net Income | 1,359.99 | 1,006.39 | 1,410.53 | 1,527.70 | 1,546.52 | 2,404.87 | 2,516.75 | 2,801.91 | 4,121.55 | 4,121.55 | ||||||||||
EPS | 16.93 | 12.52 | 17.53 | 18.97 | 19.19 | 29.82 | 31.20 | 34.72 | 51.05 | 51.06 | ||||||||||
DPS | 2.00 | 2.00 | 3.00 | 3.00 | 4.00 | 5.00 | 5.00 | 8.50 | 13.00 | 8.50 | ||||||||||
Payout ratio | 0.12 | 0.16 | 0.17 | 0.16 | 0.21 | 0.17 | 0.16 | 0.24 | 0.25 | 0.17 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Cipla Ltd | 29.17 | 5.07 | 0.87% |
Sun Pharmaceutical Industries Ltd | 38.18 | 6.16 | 0.89% |
Zydus Lifesciences Ltd | 28.02 | 5.49 | 0.28% |
Dr Reddy's Laboratories Ltd | 19.02 | 4.56 | 0.63% |
Price Comparison
Compare CIPLA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Cipla Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Manufacturing Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.2550% | Percentage of the fund’s portfolio invested in the stock 2.94% | Change in the portfolio weight of the stock over the last 3 months 2.94% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 10/75 (-1) |
Axis India Manufacturing Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.1000% | Percentage of the fund’s portfolio invested in the stock 2.30% | Change in the portfolio weight of the stock over the last 3 months -0.23% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/79 (-4) |
HDFC Pharma and Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0585% | Percentage of the fund’s portfolio invested in the stock 8.43% | Change in the portfolio weight of the stock over the last 3 months 0.48% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 2/39 (0) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Cipla Ltd
Events
Dividend Trend
No Dividend Cuts
CIPLA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.87%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.73 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
Cash Dividend
Ex DateEx DateAug 2, 2024
Dividend/Share
₹13.00
Ex DateEx Date
Aug 2, 2024
Past Dividends
Cash Dividend
Ex DateEx DateJul 21, 2023
Dividend/Share
₹8.50
Ex DateEx Date
Jul 21, 2023
Cash Dividend
Ex DateEx DateAug 8, 2022
Dividend/Share
₹5.00
Ex DateEx Date
Aug 8, 2022
Cash Dividend
Ex DateEx DateAug 9, 2021
Dividend/Share
₹5.00
Ex DateEx Date
Aug 9, 2021
Cash Dividend
Ex DateEx DateMar 19, 2020
Dividend/Share
₹3.00
Ex DateEx Date
Mar 19, 2020
Cash Dividend
Ex DateEx DateMar 19, 2020
Dividend/Share
₹1.00
Ex DateEx Date
Mar 19, 2020
News & Opinions
Orchid Pharma rises 4% on deal with Cipla to roll out new UTI drug in India
1 day ago•Business Standard
Orchid Pharma partners with Cipla for pan-India distribution of Cefepime-Enmetazobactam
3 days ago•Business Standard
Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India
4 days ago•Business Standard
Orchid Pharma join hands with Cipla to launch new antibiotic in India
4 days ago•Business Standard
News Video
Market Opening LIVE | Nifty Opens Below 23,400, Sensex Down 440 Points; Cipla, JSW Energy In Focus
1 week ago•CNBC-TV18
Stocks To Watch: TVS Motors, IREDA, SAIL, Religare, Adani Ports, Cipla, And Others - News18
1 week ago•News18
Stocks to watch on June 24: Sun Pharma, Cipla, Lupin, Vedanta, Tata Steel
1 week ago•Business Standard
Cipla Goa facility gets 6 USFDA observations
1 week ago•Business Standard
Takeda Gives Sun Pharma, Cipla Rights to Commercialise Gastro Drug in India - News18
1 week ago•News18
Cipla invests additional 3 mn euro in mRNA technology company Ethris
2 weeks ago•Business Standard
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 9.51%, vs industry avg of 9%
Decreasing Market Share
Over the last 5 years, market share decreased from 7.6% to 7.35%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 21.96%, vs industry avg of 15.09%